ERBB2 and cancer: These drugs are recommended to treat metastatic breast cancer in hormone receptor–positive (HR+) and HER2-negative (HER2−) patients and are considered a successful innovation in the cancer pharmaceutical industry due to their oral usage and good pharmacological responses.